Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

or (iii) otherwise qualify for an exemption under American Century's closed fund policy. The Russell 1000® Index measures the performance of the 1,000 largest companies in the Russell 3000® Index (the ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...